1. Inicio
  2. Publicaciones
  3. Targeted-lung delivery of dexamethasone using gated mesoporous silica nanoparticles. A new therapeutic approach for acute lung injury treatment.

Targeted-lung delivery of dexamethasone using gated mesoporous silica nanoparticles. A new therapeutic approach for acute lung injury treatment.

Fecha de publicación: Fecha Ahead of Print:

Autores de CIPF

Participantes ajenos a CIPF

  • Amorós P

Grupos de Investigación

Abstract

Acute lung injury (ALI) is a critical inflammatory syndrome, characterized by increased diffuse inflammation and severe lung damage, which represents a clinical concern due to the high morbidity and mortality in critical patients. In last years, there has been a need to develop more effective treatments for ALI, and targeted drug delivery to inflamed lungs has become an attractive research field. Here, we present a nanodevice based on mesoporous silica nanoparticles loaded with dexamethasone (a glucocorticoid extensively used for ALI treatment) and capped with a peptide that targets the TNFR1 receptor expressed in pro-inflammatory macrophages (TNFR-Dex-MSNs) and avoids cargo leakage. TNFR-Dex-MSNs nanoparticles are preferentially internalized by pro-inflammatory macrophages, which overexpressed the TNFR1 receptor, with the subsequent cargo release upon the enzymatic hydrolysis of the capping peptide in lysosomes. Moreover, TNFR-Dex-MSNs are able to reduce the levels of TNF-a and IL-1ß cytokines in activated pro-inflammatory M1 macrophages. The anti-inflammatory effect of TNFR-Dex-MSNs is also tested in an in vivo ALI mice model. The administered nanodevice (intravenously by tail vein injection) accumulated in the injured lungs and the controlled dexamethasone release reduces markedly the inflammatory response (TNF-a IL-6 and IL-1ß levels). The attenuation in lung damage, after treatment with TNFR-Dex-MSNs, is also confirmed by histopathological studies. Besides, the targeted-lung dexamethasone delivery results in a decrease of dexamethasone derived side-effects, suggesting that targeted nanoparticles can be used for therapy in ALI and could help to overcome the clinical limitations of current treatments.

Datos de la publicación

ISSN/ISSNe:
0168-3659, 1873-4995

JOURNAL OF CONTROLLED RELEASE  ELSEVIER SCIENCE BV

Tipo:
Article
Páginas:
14-26
PubMed:
34265332

Citas Recibidas en Web of Science: 52

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • ALI treatment, Dexamethasone delivery, Gated nanodevices, Mesoporous silica nanoparticles, TNFR peptide

Campos de Estudio

Proyectos asociados

Ensuring long-term sustainability of excellence in chemical biology within Europe and beyond

Investigador Principal: MARIA JESUS VICENT DOCON

COMMISSION OF EUROPEAN COMMUNITIES . 2019

Red de Transtornos Adictivos

Investigador Principal: CONSUELO GUERRI SIRERA

INSTITUTO DE SALUD CARLOS III . 2017

Descifrando y modulando el interactoma transmembrana de las proteínas Bcl-2 como diana antitumoral

Investigador Principal: MARIA MAR ORZÁEZ CALATAYUD

MINISTERIO DE ECON. Y COMPET. . 2018

Nuevo biomaterial bio-activo para la regeneración de lesiones medulares

Investigador Principal: M VICTORIA MORENO MANZANO

MINISTERIO DE ECON. Y COMPET. . 2019

MEMBDEATH: Muerte celular y membranas: un nuevo nicho en la lucha contra el cáncer. Colab con la UV, no recibimos financiación

Investigador Principal: MARIA MAR ORZÁEZ CALATAYUD

CONSELLERIA DE EDUCACION . 2019

Compartir